Zydus Lifesciences: Subsidiary Zylidac Bio Teams Up With Prolific Machines To Enhance Optogenetics-Based Biologics Production To GMP Standards.

 21 Oct 2026 06:31 PM

Zydus Lifesciences: Subsidiary Zylidac Bio Teams Up With Prolific Machines To Enhance Optogenetics-Based Biologics Production To GMP Standards.

Zydus Lifesciences: Gets Final USFDA Approval For Estradiol And Levonorgestrel Transdermal System; Eligible For 180-Day CGT Exclusivity; Expected Annual Sales Around USD 45.7 Million In The US

 21 Oct 2026 11:11 AM

Zydus Lifesciences: Gets Final USFDA Approval For Estradiol And Levonorgestrel Transdermal System; Eligible For 180-Day CGT Exclusivity; Expected Annual Sales Around USD 45.7 Million In The US

Zydus Lifesciences: Company Signs Deal With Sri Lanka's Board Of Investment To Build A Pharmaceutical Plant; Project Will Cost Over $20 Million; Operations To Begin In 2028.

 15 Oct 2026 11:33 AM

Zydus Lifesciences: Company Signs Deal With Sri Lanka's Board Of Investment To Build A Pharmaceutical Plant; Project Will Cost Over $20 Million; Operations To Begin In 2028.

Zydus Lifesciences: Bernstein on Zydus Lifesciences Maintains Buy, Target Price ₹1,457; US FDA acceptance for review of FYB206, a Keytruda biosimilar, reinforces Zydus’ strategy of building a biologics and novel-drug franchise for the US; Bernstein sees it as the first and currently only pembrolizumab biosimilar accepted for review, with potential FDA action in Q3 2027, estimates a US$7–8bn contestable year-one post-patent-loss IV market and projects US$500mn in base-case gross end-market sales for Zydus, translating to around US$150mn annual gross profit before commercial expenses under its licensing assumptions.

 14 Oct 2026 08:56 AM

Zydus Lifesciences: Bernstein on Zydus Lifesciences Maintains Buy, Target Price ₹1,457; US FDA acceptance for review of FYB206, a Keytruda biosimilar, reinforces Zydus’ strategy of building a biologics and novel-drug franchise for the US; Bernstein sees it as the first and currently only pembrolizumab biosimilar accepted for review, with potential FDA action in Q3 2027, estimates a US$7–8bn contestable year-one post-patent-loss IV market and projects US$500mn in base-case gross end-market sales for Zydus, translating to around US$150mn annual gross profit before commercial expenses under its licensing assumptions.

Zydus Lifesciences: USFDA Inspection at Moraiya Plant Ends with 5 Observations, Company Plans to Resolve Issues Quickly.

 13 Oct 2026 08:32 PM

Zydus Lifesciences: USFDA Inspection at Moraiya Plant Ends with 5 Observations, Company Plans to Resolve Issues Quickly.

Zydus Lifesciences: Company's FYB206 is the First Keytruda Biosimilar Accepted for USFDA Review.

 13 Oct 2026 09:51 AM

Zydus Lifesciences: Company's FYB206 is the First Keytruda Biosimilar Accepted for USFDA Review.

Zydus Life: Keytruda Global Sales Hit USD 31.7 Billion, With Combined Revenue of USD 16.40 Billion in First Half of 2026

 13 Oct 2026 09:52 AM

Zydus Life: Keytruda Global Sales Hit USD 31.7 Billion, With Combined Revenue of USD 16.40 Billion in First Half of 2026

Zydus Lifesciences: Co MD States Application Approval Is Key For Wider Access To Affordable Pembrolizumab Treatment In The U.S. And Canada As Demand For Quality Oncology Care Grows.

 13 Oct 2026 09:52 AM

Zydus Lifesciences: Co MD States Application Approval Is Key For Wider Access To Affordable Pembrolizumab Treatment In The U.S. And Canada As Demand For Quality Oncology Care Grows.

Zydus Life: Bernstein on Zydus Life Outperform, Target Price ₹1,457; launch of the first generic version of Bayer’s Adempas® in the US reinforces Zydus’ differentiated Para IV commercialisation capability through partnerships; expects US$30–35mn FY27E sales, translating to ₹1.9–2.4bn revenue and 0.7–1.0% FY27E EPS contribution at 30–35% margin.

 08 Oct 2026 08:53 AM

Zydus Life: Bernstein on Zydus Life Outperform, Target Price ₹1,457; launch of the first generic version of Bayer’s Adempas® in the US reinforces Zydus’ differentiated Para IV commercialisation capability through partnerships; expects US$30–35mn FY27E sales, translating to ₹1.9–2.4bn revenue and 0.7–1.0% FY27E EPS contribution at 30–35% margin.

Zydus Lifesciences: Launches First Generic Version Of Adempas (Riociguat Tablets) In The US With MSN Laboratories.

 05 Oct 2026 08:45 PM

Zydus Lifesciences: Launches First Generic Version Of Adempas (Riociguat Tablets) In The US With MSN Laboratories.

Zydus Lifesciences: Co Extends Deadline For Investment In Zydus Sunshine Lifesciences To December 2026; Joint Venture With Sunshine Healthcare Lanka Limited Will Be 50:50.

 02 Oct 2026 02:32 PM

Zydus Lifesciences: Co Extends Deadline For Investment In Zydus Sunshine Lifesciences To December 2026; Joint Venture With Sunshine Healthcare Lanka Limited Will Be 50:50.

Zydus Lifesciences: USFDA Inspection of Ahmedabad SEZ II Plant Ends with One Observation, No Issues Found with Data Integrity.

 28 Sep 2026 06:05 PM

Zydus Lifesciences: USFDA Inspection of Ahmedabad SEZ II Plant Ends with One Observation, No Issues Found with Data Integrity.

Zydus Lifesciences: USFDA Inspection Of Co’s Pharmacovigilance And Post-marketing Surveillance System At Its New Jersey Office Concludes With Nil Observations.

 26 Sep 2026 02:53 PM

Zydus Lifesciences: USFDA Inspection Of Co’s Pharmacovigilance And Post-marketing Surveillance System At Its New Jersey Office Concludes With Nil Observations.

Zydus Life: Bernstein on Zydus Life Maintains Outperform with Target Price of ₹1,457 as Novartis discontinuing VHB937 improves the commercial landscape for Usnoflast in ALS, with positive success prospects, US FDA priority review and orphan designation supporting potential high returns if Phase IIb data demonstrates meaningful efficacy.

 18 Sep 2026 08:44 AM

Zydus Life: Bernstein on Zydus Life Maintains Outperform with Target Price of ₹1,457 as Novartis discontinuing VHB937 improves the commercial landscape for Usnoflast in ALS, with positive success prospects, US FDA priority review and orphan designation supporting potential high returns if Phase IIb data demonstrates meaningful efficacy.

Zydus Lifesciences: Reports Good Results From Its Evidence-X Phase II(B) Clinical Trial For Saroglitazar MG In MASH; The Trial Met Its Main Goal Of Resolving Steatohepatitis Without Increasing Fibrosis.

 31 Aug 2026 10:44 AM

Zydus Lifesciences: Reports Good Results From Its Evidence-X Phase II(B) Clinical Trial For Saroglitazar MG In MASH; The Trial Met Its Main Goal Of Resolving Steatohepatitis Without Increasing Fibrosis.

Zydus Life: Macquarie on Zydus Life Maintains Outperform with Target Price of ₹1,285 as strategic mix shift is expected to lift EBITDA margins to 27–28%, Saroglitazar and a robust US generics pipeline strengthen growth visibility, while domestic business is expected to outgrow IPM by 300–500bps and international formulations and consumer wellness remain growth drivers.

 27 Aug 2026 08:55 AM

Zydus Life: Macquarie on Zydus Life Maintains Outperform with Target Price of ₹1,285 as strategic mix shift is expected to lift EBITDA margins to 27–28%, Saroglitazar and a robust US generics pipeline strengthen growth visibility, while domestic business is expected to outgrow IPM by 300–500bps and international formulations and consumer wellness remain growth drivers.

Zydus Lifesciences: Co. Incorporates Unit Named Zydus Global Treasury Centre Ifsc Limited In Gift City, Gandhinagar.

 26 Aug 2026 11:13 AM

Zydus Lifesciences: Co. Incorporates Unit Named Zydus Global Treasury Centre Ifsc Limited In Gift City, Gandhinagar.

Zydus Lifesciences: Company Gets Final USFDA Approval For Ascorbic Acid Injection With 180-Day CGT Exclusivity; Product To Treat Scurvy, Made In USFDA-Approved Plant In Gujarat.

 21 Aug 2026 01:54 PM

Zydus Lifesciences: Company Gets Final USFDA Approval For Ascorbic Acid Injection With 180-Day CGT Exclusivity; Product To Treat Scurvy, Made In USFDA-Approved Plant In Gujarat.

HC bars Zydus Life from launching drug with Novartis-patent Dabrafenib

 18 Aug 2026 11:28 AM

HC bars Zydus Life from launching drug with Novartis-patent Dabrafenib

Zydus: Jefferies on Zydus Maintains Buy with Target Price of ₹1,370 as 1QFY27 growth remained strong across India and international markets, US sales rose 5% QoQ on new launches, FY27 guidance was retained, and FTF launches and innovative products support growth beyond FY27 despite a 3% FY27 EPS cut.

 12 Aug 2026 09:04 AM

Zydus: Jefferies on Zydus Maintains Buy with Target Price of ₹1,370 as 1QFY27 growth remained strong across India and international markets, US sales rose 5% QoQ on new launches, FY27 guidance was retained, and FTF launches and innovative products support growth beyond FY27 despite a 3% FY27 EPS cut.